HPV Mutation Detail Information

Virus Mutation HPV Mutation C428A


Basic Characteristics of Mutations
Mutation Site C428A
Mutation Site Sentence We show that co-assembly between any pair of C175A and C428A mutants across at least nine HPV genotypes occurs at a preferred equal molar stoichiometry, irrespective of the type or number of L1 sequences.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region L1
Standardized Encoding Gene L1
Genotype/Subtype HPV6;HPV11;HPV16;HPV18;HPV31;HPV26;HPV33;HPV35;HPV39;HPV45;HPV51;HPV52;HPV53;HPV56;HPV58;HPV59;HPV66;HPV68;HPV69;HPV70
Viral Reference AAQ92369;P17388;NP_041787.1;P24838;P36741;ACV88631.1;AML80965;NP_041848;P36743;AFS33402;CAA54856;ABO76893;AGU90787;AHV83654.1;P50793;AAC80442.1;AMY16565;AAA46935.1;ANA05496;P27232
Functional Impact and Mechanisms
Disease -
Immune -
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location -
Literature Information
PMID 32503989
Title Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles
Author Wang D,Liu X,Wei M,Qian C,Song S,Chen J,Wang Z,Xu Q,Yang Y,He M,Chi X,Huang S,Li T,Kong Z,Zheng Q,Yu H,Wang Y,Zhao Q,Zhang J,Xia N,Gu Y,Li S
Journal Nature communications
Journal Info 2020 Jun 5;11(1):2841
Abstract The capsid of human papillomavirus (HPV) spontaneously arranges into a T = 7 icosahedral particle with 72 L1 pentameric capsomeres associating via disulfide bonds between Cys175 and Cys428. Here, we design a capsomere-hybrid virus-like particle (chVLP) to accommodate multiple types of L1 pentamers by the reciprocal assembly of single C175A and C428A L1 mutants, either of which alone encumbers L1 pentamer particle self-assembly. We show that co-assembly between any pair of C175A and C428A mutants across at least nine HPV genotypes occurs at a preferred equal molar stoichiometry, irrespective of the type or number of L1 sequences. A nine-valent chVLP vaccine-formed through the structural clustering of HPV epitopes-confers neutralization titers that are comparable with that of Gardasil 9 and elicits minor cross-neutralizing antibodies against some heterologous HPV types. These findings may pave the way for a new vaccine design that targets multiple pathogenic variants or cancer cells bearing diverse neoantigens.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.